Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
about
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesCellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.Novel developments in the use of antimetabolites.TAS-102, a novel antitumor agent: a review of the mechanism of action.TAS-102: a novel antimetabolite for the 21st century.A novel antimetabolite: TAS-102 for metastatic colorectal cancer.Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance.Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent.Trifluorothymidine induces cell death independently of p53.Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy.Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
P2860
Q26777679-A3814B16-1BDD-442B-B1DF-C645876EAB58Q33914993-DD8E4F53-8AF0-4405-9972-34ABB1DEBCC7Q34620205-6DA1D666-BDB1-4303-B2F0-4B63C55AFDD5Q36858129-C617DB2D-BE0F-4598-B36C-DB7358BE0EF8Q38204673-2FF067D2-56AA-45FF-85F9-D75477B4B752Q38221152-5626737F-DAFE-4CA8-87EB-0C4C470547D7Q38597310-D3A23362-8E39-431A-9444-1D2CEE95F651Q38652269-333BCBAA-454C-4633-B6A1-B32658C06B94Q38671965-2CC12561-AD72-4A58-B4FD-8B0FF2409EC0Q39558883-20DF429A-5C3A-4C94-989A-8B267E3EFC39Q39830999-30ED2042-82EA-4FD9-9609-CA995D446B86Q39924293-52AFE2AC-E5F6-425D-B525-1006C849EE1AQ39965268-4936DEEF-7E15-449F-BC87-A2CB69820C24Q41195691-482F613A-E023-4F66-9BB8-837AACA2F87BQ42361962-9F0178F1-A378-488F-981B-C52302D0A2D8Q58698641-F7E16FEC-DE36-48E4-9780-3DB9A358C08C
P2860
Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mechanism of trifluorothymidin ...... ty to colorectal cancer cells.
@ast
Mechanism of trifluorothymidin ...... ty to colorectal cancer cells.
@en
type
label
Mechanism of trifluorothymidin ...... ty to colorectal cancer cells.
@ast
Mechanism of trifluorothymidin ...... ty to colorectal cancer cells.
@en
prefLabel
Mechanism of trifluorothymidin ...... ty to colorectal cancer cells.
@ast
Mechanism of trifluorothymidin ...... ty to colorectal cancer cells.
@en
P2093
P2860
P356
P1476
Mechanism of trifluorothymidin ...... ty to colorectal cancer cells.
@en
P2093
G J Peters
K van der Born
M Fukushima
O H Temmink
S P Ackland
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603549
P407
P577
2007-01-01T00:00:00Z
P5875
P6179
1030729110